维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="Fanale M"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Preliminary report ofmulticenter prospective phase D study of DA-EPOCH-R inmycrearranged aggressive B-cell lymphoma 显示文摘	Dunleavy K Fanale M Lacasce A	2014	ASH AnnualMeeting2014，，：	1
2	Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnose advanced stage classical Hodgkin's Lymphoma:Results of long follow up and comparison to institutional historical data显示文摘	Copeland AR Cao Y Fanale M	2009	Blood2009，114，：	1
3	Defining a population of HodgKin's Lymphoma显示文摘	Horning S Fanale M Devos S	2007	Blood2007，110，10：	1
4	Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma(HL)显示文摘	Younes A Pro B Fanale M	2007	Blood2007，110，11：	1
5	Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment显示文摘	Fanale M	2013	Hematology Am Soc Hematol Educ Pro- gram2013，2013，：	1
6	Final report of a phase-II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin Lymphoma:Results of long follow up and comparison to institutional historical data显示文摘	Copeland AR Cao Y Fanale M	2009	Blood2009，114，8：	1
7	Combination therapy of Ad-mda-7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells显示文摘	MoKENZIE T LIU Y FANALE M	2004	Surgery2004，136，2：	1
8	Induction of apoptosis in human lung cancer cells ollowing treatment with amifostine and an adenoviral vector containing wild-type p53 显示文摘	PATAER A FANALE M A ROTH J A	2006	Cancer Gene Ther2006，13，80：	1
9	Phase Ⅰ study of a novel oral Janus kinase 2 inhibitor,SB1518,in patients with relapsed lymphoma:evidence of clinical and biologic activity in multiple lymphoma subtypes显示文摘	Younes A Romaguera J Fanale M	2012	J Clin Oncol2012，30，：	1
10	A phase Ⅰ study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma显示文摘	Fanale M A Fayad L E Pro B	2008	Blood2008，112，：	1
11	Combination therapy of Ad- mda7 and trastuzumab increases cell death in Her-2/neu-overex- pressing breast cancer cells显示文摘	Mckenzie T Liu Y Fanale M	2004	Surgery2004，136，2：	1
12	A novel prognostic scoring system for NLPHL 显示文摘	Fanale M	2013	Blood2013，122，26：	1
13	Phase I study of a novel oralJanus Kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma:evidence of clinical and biologic activety in multiple lymphomasubtypes显示文摘	Younes A Romaguera J Fanale M	2012	J Clin Oncol2012，30，：	1
14	Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL)显示文摘	Younes A Pro B Fanale M	2007	Blood2007，110，：	1
15	Final report of a phase-Ⅱ study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma:Results of long follow up and comparison to institutional historical data显示文摘	Copeland A R Cao Y Fanale M	2009	Blood2009，114，：	1
16	Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neuoverexpressing breast cancer cells显示文摘	McKenzie T Liu Y Fanale M	2004	Surgery2004，136，2：	1
17	Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells显示文摘	McKenzie T Liu Y Fanale M	2004	Surgery2004，136，2：	1
18	PhaseⅡstudy of an Akt inhibitor MK2206 in patients with relapsed or refractory lymphoma显示文摘	Oki Y Fanale M Romaguera J	2015	Br J Haematol2015，171，4：	1
19	Combination therapy of Ad-mda-7 and trastuzumab increases cell death in Her-2/neuoverexpressing breast cancer cells显示文摘	Mokenzie T Liu Y Fanale M etal	2004	Surgery2004，136，2：	1
20	A phase 1B safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low grade non-Hodgkin lymphoma显示文摘	Yee L Fanale M Dimick K	2007	J Clin Oncol2007，25，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示